1614246-34-2

Upstream product

• 67-56-1 methanol 
• 779329-61-2 1-bromo-4-(ethylsulfonyl)-2-fluorobenzene 
• 1215295-91-2 4-bromo-3-methoxybenzene-1-sulfonyl chloride 
• 75-03-6 ethyl iodide 
• 351003-51-5 4-bromo-3-fluorobenzene-1-sulfonyl chloride 
• 1620220-66-7 C₆H₆BrFN₂O₂S 
• 1614246-35-3 1-bromo-4-(ethylthio)-2-methoxybenzene 
• 450-88-4 1-bromo-4-fluoro-2-methoxybenzene 
• 147460-41-1 2-bromo-5-fluorophenol 
• 124-41-4 sodium methylate 

Downstream Products

• 1614246-66-0 2-(6-chloro-4'-(ethylsulfonyl)-2'-methoxy-[1,1'-biphenyl]-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1614246-68-2 2-(4'-(ethylsulfonyl)-2',6-dimethoxy-[1,1'-biphenyl]-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1614246-14-8 5-(7-ethyl-7H-imidazo[4,5-c]pyridazin-4-yl)-4'-(ethylsulfonyl)-2'-methoxy-[1,1'-biphenyl]-2-carbonitrile 
• 1614246-88-6 4'-(ethylsulfonyl)-2'-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)[1,1'-biphenyl]-2-ol 
• 1614246-15-9 5-(7-ethyl-7H-imidazo[4,5-c]pyridazin-4-yl)-4'-(ethylsulfonyl)-2'-methoxy-[1,1'-biphenyl]-2-ol 
• 1614245-70-3 4-(4'-(ethylsulfonyl)-6-fluoro-2'-methoxybiphenyl-3-yl)-7-ethyl-7H-imidazo[4,5-c]pyridazine 
• 1614246-10-4 7-cyclopentyl-4-(4'-(ethylsulfonyl)-6-fluoro-2'-methoxy-[1,1'-biphenyl]-3-yl)-7H-imidazo[4,5-c]pyridazine 
• 1614246-53-5 2-(4'-(ethylsulfonyl)-6-fluoro-2'-methoxy-[1,1'-biphenyl]-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1614246-36-4 2-(4-(ethylsulfonyl)-2-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1403329-99-6 1-bromo-2-(difluoromethoxy)-4-(ethylsulfonyl)benzene 

Relevant academic research and scientific papers

Design and Identification of a Novel, Functionally Subtype Selective GABAA Positive Allosteric Modulator (PF-06372865)

The design, optimization, and evaluation of a series of novel imidazopyridazine-based subtype-selective positive allosteric modulators (PAMs) for the GABAA ligand-gated ion channel are described. From a set of initial hits multiple subseries were designed and evaluated based on binding affinity and functional activity. As designing in the desired level of functional selectivity proved difficult, a probability-based assessment was performed to focus the project's efforts on a single subseries that had the greatest odds of delivering the target profile. These efforts ultimately led to the identification of two precandidates from this subseries, which were advanced to preclinical safety studies and subsequently to the identification of the clinical candidate PF-06372865.

Synthesis of functionalized cyanopyrazoles via magnesium bases

4-Alkyl- and 4-H-pyrazoles were sequentially metalated using TMPMgCl·LiCl, and their reaction with electrophiles afforded 3-aryl-4-alkyl-5-cyanopyrazoles.

Chemical Compounds

The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the GABAA receptor. They are useful in the treatment of a number of conditions, including pain.